Antineoplastic AgentsRadiation InjuriesRadiation DosageRadiation, IonizingNeoplasmsDose-Response Relationship, RadiationRadiation ToleranceRadiotherapyCell Line, TumorRadiotherapy DosageCombined Modality TherapyDrug Screening Assays, AntitumorRadiationRadiation OncologyRadiation ProtectionRadiotherapy, ConformalRadiation MonitoringApoptosisRadiotherapy, Intensity-ModulatedDrug Resistance, NeoplasmDoxorubicinCisplatinCell SurvivalBreast NeoplasmsDose FractionationMice, NudeRadiotherapy, AdjuvantAntineoplastic Agents, PhytogenicXenograft Model Antitumor AssaysRadiotherapy Planning, Computer-AssistedDrug Delivery SystemsRadiation PneumonitisRadiation-Sensitizing AgentsProstatic NeoplasmsNeoplasms, Radiation-InducedBrachytherapyLung NeoplasmsTumor Cells, CulturedAntibiotics, AntineoplasticRadiometryCell ProliferationGamma RaysAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeDNA DamageBrain NeoplasmsRadiation Injuries, ExperimentalRadiosurgeryNeoplasm Recurrence, LocalHead and Neck NeoplasmsGene Expression Regulation, NeoplasticDrug CarriersPaclitaxelColonic NeoplasmsCarcinoma, Squamous CellFluorouracilCosmic RadiationNeoplasm StagingTumor BurdenEtoposideDose-Response Relationship, DrugAdenocarcinomaCell CycleTime FactorsRadiotherapy, Computer-AssistedSurvival AnalysisMolecular Targeted TherapyCranial IrradiationCamptothecinTumor Suppressor Protein p53Retrospective StudiesNeoplasm TransplantationNeoplasm MetastasisSurvival RateRadiotherapy, Image-GuidedParticle AcceleratorsClinical Trials as TopicOvarian NeoplasmsPrognosisRadiation-Protective AgentsNeoplasm ProteinsDisease-Free SurvivalPancreatic NeoplasmsInhibitory Concentration 50RadiodermatitisEllipticinesDrug SynergismFollow-Up StudiesBackground RadiationDrug DesignCarcinoma, Non-Small-Cell LungSignal TransductionUltraviolet RaysDrug Resistance, MultipleRadiotherapy, High-EnergyAntimetabolites, AntineoplasticEnzyme InhibitorsChemotherapy, AdjuvantP-GlycoproteinNanoparticles